Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.55 |
| ▸ | ITGAV | P06756 | 8/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | MC4R | P32245 | 8/20 | 0.54 |
| ▸ | MC5R | P33032 | 8/20 | 0.54 |
| ▸ | MC3R | P41968 | 8/20 | 0.54 |
| ▸ | MC1R | Q01726 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885799 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL7743878 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL16946584 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13107808 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL16938095 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL18968795 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12547669 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL19581486 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21475019 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12808284 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637836-A1 | CYCLIC PEPTIDE-BASED LYSOSOME TARGETING DEGRADERS | Wisconsin Alumni Research Foundation (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250197863-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC (US) | 2025-06-19 | — | — | US | claimed |
| EP-4493570-A2 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2024163404-A1 | CYCLIC PEPTIDE-BASED LYSOSOME TARGETING DEGRADERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | WO | claimed |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2024-01-18 | — | — | US | claimed |
| US-20230357774-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. | 2023-11-09 | — | — | US | claimed |
| WO-2023178144-A2 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2022140365-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2022072356-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3976059-A2 | TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. (US) | 2022-04-06 | — | — | EP | claimed |
| US-20260132230-A1 | LIPID-POLYMER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | MIRUS BIO LLC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026090085-A1 | TREATMENT OF CD33 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732849-A1 | METHOD FOR IMPROVING STABILITY OF NUCLEIC ACID IN BLOOD AND IMPROVING TARGETING EFFICIENCY OF NUCLEIC ACID | Kawasaki Institute of Industrial Promotion (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731273-A2 | HYDROGEL FORMULATIONS AND METHODS OF USE THEREOF | Tempo Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108638-A1 | 68GA- AND 64CU -NODAGA-E[C(RGDYK)]2 FOR USE AS PET TRACERS IN THE IMAGING OF ANGIOGENESIS IN HUMANS | RIGSHOSPITALET (DK) | 2026-04-23 | — | — | US | disclosed |
| US-20070134259-A1 | Methods and compositions for pharmacologially controlled targeted immunotherapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2007-06-14 | — | — | US | disclosed |
| US-20070134259-A1 | Methods and compositions for pharmacologially controlled targeted immunotherapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2007-06-14 | — | — | US | disclosed |
| US-20070116646-A1 | Optical imaging of endometriosis | KLAVENESS JO | 2007-05-24 | — | — | US | disclosed |
| WO-2007056870-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICALLY CONTROLLED TARGETED IMMUNOTHERAPY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2007-05-24 | — | — | WO | disclosed |
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108638-A1 | 68GA- AND 64CU -NODAGA-E[C(RGDYK)]2 FOR USE AS PET TRACERS IN THE IMAGING OF ANGIOGENESIS IN HUMANS | VEGFA, FLT1, HIF1A | ITGB3 324/4885ITGAV 597/4885ITGB5 1397/4885 |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | CSGALNACT1, B3GAT3, UGGT1 | ITGB3 247/4885ITGAV 142/4885ITGB5 278/4885 |
| US-20070134259-A1 | Methods and compositions for pharmacologially controlled targeted immunotherapy | HAVCR2, FCGR3B, CD47 | ITGB3 505/4885ITGAV 355/4885ITGB5 554/4885 |
| US-20250197863-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | CSGALNACT1, B3GAT3, UGGT1 | ITGB3 247/4885ITGAV 142/4885ITGB5 278/4885 |
| US-20260132230-A1 | LIPID-POLYMER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | LIPE, PHOSPHO1, ATF4 | ITGB3 4335/4885ITGAV 4152/4885ITGB5 4744/4885 |
| US-20070116646-A1 | Optical imaging of endometriosis | LGALS3BP, SDF4, OGFRL1 | ITGB3 599/4885ITGAV 743/4885ITGB5 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.